252 related articles for article (PubMed ID: 35010633)
1. Substance P and Neurokinin 1 Receptor in Chronic Inflammation and Cancer of the Head and Neck: A Review of the Literature.
Esteban F; Ramos-García P; Muñoz M; González-Moles MÁ
Int J Environ Res Public Health; 2021 Dec; 19(1):. PubMed ID: 35010633
[TBL] [Abstract][Full Text] [Related]
2. Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells; Effects independent of Substance P.
Nizam E; Erin N
Biomed Pharmacother; 2018 Dec; 108():263-270. PubMed ID: 30223097
[TBL] [Abstract][Full Text] [Related]
3. New insight into the role of substance P/neurokinin-1 receptor system in breast cancer progression and its crosstalk with microRNAs.
Ebrahimi S; Javid H; Alaei A; Hashemy SI
Clin Genet; 2020 Oct; 98(4):322-330. PubMed ID: 32266968
[TBL] [Abstract][Full Text] [Related]
4. Expression of substance P, neurokinin 1 receptor, Ki-67 and pyruvate kinase M2 in hormone receptor negative breast cancer and evaluation of impact on overall survival.
Al-Keilani MS; Bdeir R; Elstaty RI; Alqudah MA
BMC Cancer; 2023 Feb; 23(1):158. PubMed ID: 36797689
[TBL] [Abstract][Full Text] [Related]
5. SP promotes cell proliferation in esophageal squamous cell carcinoma through the NK1R/Hes1 axis.
Wang F; Liu S; Liu J; Feng F; Guo Y; Zhang W; Zheng G; Wang Q; Cai L; Guo M; Lian X; Xu G; Zhang H
Biochem Biophys Res Commun; 2019 Jul; 514(4):1210-1216. PubMed ID: 31109645
[TBL] [Abstract][Full Text] [Related]
6. Substance P enhances the local activation of NK
Jeong YM; Cheng XW; Lee KH; Lee S; Cho H; Kim W
BMC Mol Cell Biol; 2020 Jun; 21(1):41. PubMed ID: 32517655
[TBL] [Abstract][Full Text] [Related]
7. Tachykinin Receptor-Selectivity of the Potential Glioblastoma-Targeted Therapy, DOTA-[Thi
Suthiram J; Pieters A; Mohamed Moosa Z; Zeevaart JR; Sathekge MM; Ebenhan T; Anderson RC; Newton CL
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768456
[TBL] [Abstract][Full Text] [Related]
8. Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer.
Mozafari M; Ebrahimi S; Darban RA; Hashemy SI
Mol Biol Rep; 2022 Feb; 49(2):1067-1076. PubMed ID: 34766230
[TBL] [Abstract][Full Text] [Related]
9. The neuropeptide substance P/neurokinin-1 receptor system and diabetes: From mechanism to therapy.
Kokabi F; Ebrahimi S; Mirzavi F; Ghiasi Nooghabi N; Hashemi SF; Hashemy SI
Biofactors; 2023; 49(3):534-559. PubMed ID: 36651605
[TBL] [Abstract][Full Text] [Related]
10. The emerging role of substance P/neurokinin-1 receptor signaling pathways in growth and development of tumor cells.
Javid H; Mohammadi F; Zahiri E; Hashemy SI
J Physiol Biochem; 2019 Nov; 75(4):415-421. PubMed ID: 31372898
[TBL] [Abstract][Full Text] [Related]
11. Roles of full-length and truncated neurokinin-1 receptors on tumor progression and distant metastasis in human breast cancer.
Zhou Y; Zhao L; Xiong T; Chen X; Zhang Y; Yu M; Yang J; Yao Z
Breast Cancer Res Treat; 2013 Jul; 140(1):49-61. PubMed ID: 23807418
[TBL] [Abstract][Full Text] [Related]
12. Substance P and the neurokinin-1 receptor expression in dog ileum with and without inflammation.
Polidoro G; Giancola F; Fracassi F; Pietra M; Bettini G; Asti M; Chiocchetti R
Res Vet Sci; 2017 Oct; 114():297-307. PubMed ID: 28628846
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of serum level of substance P and tissue distribution of NK-1 receptor in colorectal cancer.
Lorestani S; Ghahremanloo A; Jangjoo A; Abedi M; Hashemy SI
Mol Biol Rep; 2020 May; 47(5):3469-3474. PubMed ID: 32277443
[TBL] [Abstract][Full Text] [Related]
14. Substance P and the Neurokinin-1 Receptor: The New CRF.
Schank JR; Heilig M
Int Rev Neurobiol; 2017; 136():151-175. PubMed ID: 29056150
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of serum level of substance P and tissue distribution of NK-1 receptor in endometrial cancer.
Gharaee N; Pourali L; Jafarian AH; Hashemy SI
Mol Biol Rep; 2018 Dec; 45(6):2257-2262. PubMed ID: 30225581
[TBL] [Abstract][Full Text] [Related]
16. Tachykinin NK1 receptor antagonist L-733,060 and substance P deletion exert neuroprotection through inhibiting oxidative stress and cell death after traumatic brain injury in mice.
Li Q; Wu X; Yang Y; Zhang Y; He F; Xu X; Zhang Z; Tao L; Luo C
Int J Biochem Cell Biol; 2019 Feb; 107():154-165. PubMed ID: 30593954
[TBL] [Abstract][Full Text] [Related]
17. Substance P activates responses correlated with tumour growth in human glioma cell lines bearing tachykinin NK1 receptors.
Palma C; Nardelli F; Manzini S; Maggi CA
Br J Cancer; 1999 Jan; 79(2):236-43. PubMed ID: 9888463
[TBL] [Abstract][Full Text] [Related]
18. MiR-34b/c-5p and the neurokinin-1 receptor regulate breast cancer cell proliferation and apoptosis.
Zhang L; Wang L; Dong D; Wang Z; Ji W; Yu M; Zhang F; Niu R; Zhou Y
Cell Prolif; 2019 Jan; 52(1):e12527. PubMed ID: 30334298
[TBL] [Abstract][Full Text] [Related]
19. SP/NK1R system regulates carcinogenesis in prostate cancer: Shedding light on the antitumoral function of aprepitant.
Ebrahimi S; Mirzavi F; Aghaee-Bakhtiari SH; Hashemy SI
Biochim Biophys Acta Mol Cell Res; 2022 May; 1869(5):119221. PubMed ID: 35134443
[TBL] [Abstract][Full Text] [Related]
20. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
